tiprankstipranks
Alebund Pharmaceuticals (Jiangsu) Limited Class H (HK:9637)
:9637
Hong Kong Market
9637
Alebund Pharmaceuticals (Jiangsu) Limited Class H
RESEARCH TOOLSreports

Alebund Pharmaceuticals (Jiangsu) Limited Class H (9637) Price & Analysis

― Followers

9637 Stock Chart & Stats

$23.00
-$1.02(-4.25%)
―
--
Day’s Range― - ―
52-Week Range$22.48 - $46.82
Previous CloseN/A
VolumeN/A
Average Volume (3M)571.28K
Market Cap
HK$5.66B
Enterprise Value$14.66K
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.42
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding235,635,480
10 Day Avg. Volume902,555
30 Day Avg. Volume571,276
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$48.86
Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A

Alebund Pharmaceuticals (Jiangsu) Limited Class H News

Alebund Wins FDA IND Clearance for First-in-Class IgA Nephropathy Drug AP308
Alebund Wins FDA IND Clearance for First-in-Class IgA Nephropathy Drug AP308
Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) has shared an update. Alebund Pharmaceuticals has secured clearance...
7d ago
9637
Alebund Pharmaceuticals Gains Stock Connect Access and Hang Seng Index Inclusion
Alebund Pharmaceuticals Gains Stock Connect Access and Hang Seng Index Inclusion
Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) has shared an announcement. Alebund Pharmaceuticals (Jiangsu) Limited has...
11d ago
9637
Alebund speeds kidney drug pipeline as Mircera sales in China more than double
Alebund speeds kidney drug pipeline as Mircera sales in China more than double
Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) has shared an update. Alebund Pharmaceuticals reported significant progress...
21d ago
9637
Alebund Pharmaceuticals Wins Shareholder Backing for Auditor Change and New Capital Mandates
Alebund Pharmaceuticals Wins Shareholder Backing for Auditor Change and New Capital Mandates
Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) just unveiled an update. Alebund Pharmaceuticals (Jiangsu) Limited reported...
1M ago
9637
Alebund Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results
Alebund Pharmaceuticals Sets Board Meeting to Approve 2026 Interim Results
Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) just unveiled an update. Alebund Pharmaceuticals has scheduled a...
1M ago
9637
Alebund’s AP301 NDA Accepted in China After Strong Phase III Dialysis Data
Alebund’s AP301 NDA Accepted in China After Strong Phase III Dialysis Data
Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) has issued an announcement. Alebund Pharmaceuticals (Jiangsu) Limited, a...
1M ago
9637
Alebund Pharmaceuticals Signals Surging Revenue and Narrowing Losses for First Half of 2026
Alebund Pharmaceuticals Signals Surging Revenue and Narrowing Losses for First Half of 2026
Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) has issued an update. Alebund Pharmaceuticals (Jiangsu) Limited reported...
1M ago
9637
Alebund Pharmaceuticals Updates Articles After H-Share Over-Allotment
Alebund Pharmaceuticals Updates Articles After H-Share Over-Allotment
An announcement from Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) is now available. Alebund Pharmaceuticals has...
2M ago
9637
Alebund Pharmaceuticals Calls EGM to Appoint New Auditor and Seek Share Issuance Mandate
Alebund Pharmaceuticals Calls EGM to Appoint New Auditor and Seek Share Issuance Mandate
Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ) has shared an announcement. Alebund Pharmaceuticals has called an...
2M ago
9637
Alebund Pharmaceuticals Fully Exercises Over-Allotment Option After Global Offering
Alebund Pharmaceuticals Fully Exercises Over-Allotment Option After Global Offering
The latest update is out from Alebund Pharmaceuticals (Jiangsu) Limited Class H ( ($HK:9637) ). Alebund Pharmaceuticals (Jiangsu)...
2M ago
9637

9637 FAQ

What was Alebund Pharmaceuticals (Jiangsu) Limited Class H’s price range in the past 12 months?
Alebund Pharmaceuticals (Jiangsu) Limited Class H lowest stock price was $22.48 and its highest was $46.82 in the past 12 months.
    What is Alebund Pharmaceuticals (Jiangsu) Limited Class H’s market cap?
    Alebund Pharmaceuticals (Jiangsu) Limited Class H’s market cap is HK$5.66B.
      When is Alebund Pharmaceuticals (Jiangsu) Limited Class H’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Alebund Pharmaceuticals (Jiangsu) Limited Class H’s earnings last quarter?
      Currently, no data Available
      Is Alebund Pharmaceuticals (Jiangsu) Limited Class H overvalued?
      According to Wall Street analysts Alebund Pharmaceuticals (Jiangsu) Limited Class H’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
        Does Alebund Pharmaceuticals (Jiangsu) Limited Class H pay dividends?
        Alebund Pharmaceuticals (Jiangsu) Limited Class H does not currently pay dividends.
        What is Alebund Pharmaceuticals (Jiangsu) Limited Class H’s EPS estimate?
        Alebund Pharmaceuticals (Jiangsu) Limited Class H’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Alebund Pharmaceuticals (Jiangsu) Limited Class H have?
        Alebund Pharmaceuticals (Jiangsu) Limited Class H has 235,635,480 shares outstanding.
          What happened to Alebund Pharmaceuticals (Jiangsu) Limited Class H’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Alebund Pharmaceuticals (Jiangsu) Limited Class H?
          Currently, no hedge funds are holding shares in HK:9637
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Alebund Pharmaceuticals (Jiangsu) Limited Class H (9637) Earnings & Revenues

            Historic Earnings Reports

            9637 Stock 12 Month Forecast

            Average Price Target

            $48.86
            {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"26":"$26","39":"$39","52":"$52","32.5":"$32.5","45.5":"$45.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":51.99,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$51.99</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.855000000000004,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":45.72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$45.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[26,32.5,39,45.5,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.46,32.11615384615385,33.77230769230769,35.42846153846154,37.08461538461539,38.74076923076923,40.39692307692308,42.05307692307693,43.70923076923077,45.36538461538461,47.02153846153846,48.67769230769231,50.33384615384615,{"y":51.99,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.46,31.875,33.29,34.705,36.120000000000005,37.535000000000004,38.95,40.365,41.78,43.19500000000001,44.61,46.025000000000006,47.440000000000005,{"y":48.855000000000004,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,30.46,31.633846153846154,32.80769230769231,33.98153846153846,35.15538461538462,36.32923076923077,37.503076923076925,38.676923076923075,39.85076923076923,41.02461538461539,42.19846153846154,43.37230769230769,44.54615384615384,{"y":45.72,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46,"date":1756674000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1759266000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1761948000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1764540000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1767218400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1769896800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1772316000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1774990800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1777582800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":46,"date":1780261200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":45.92,"date":1782853200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":27.24,"date":1785531600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.46,"date":1788210000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
            Detailed Analyst Forecast >

            Technical Analysis

            Overall Consensus
            Sell
            6Bullish
            2Neutral
            10Bearish
            Bullish
            Neutral
            Bearish
            Overall Consensus
            6
            2
            10
            Technical Analysis
            6
            2
            2
            Moving Averages
            0
            0
            8
            Technical Analysis >
            Popular Stocks